For research use only. Not for therapeutic Use.
Selnoflast (RO-7486967) Formerly known as Somalix/RG6418/IZD334, Selnoflast is an orally available inhibitor of NLRP3. Selnoflast is used in research into systemic inflammation, such as ulcerative colitis and chronic obstructive pulmonary disease[1][2].
| Catalog Number | I036202 |
| CAS Number | 2260969-36-4 |
| Synonyms | 1-(1-ethylpiperidin-4-yl)sulfonyl-3-(1,2,3,5,6,7-hexahydro-s-indacen-4-yl)urea |
| Molecular Formula | C20H29N3O3S |
| Purity | ≥95% |
| InChI | InChI=1S/C20H29N3O3S/c1-2-23-11-9-16(10-12-23)27(25,26)22-20(24)21-19-17-7-3-5-14(17)13-15-6-4-8-18(15)19/h13,16H,2-12H2,1H3,(H2,21,22,24) |
| InChIKey | OHIFQOUPTWBQLE-UHFFFAOYSA-N |
| SMILES | CCN1CCC(CC1)S(=O)(=O)NC(=O)NC2=C3CCCC3=CC4=C2CCC4 |
| Reference | [1]. Vande Walle L, et al. Drugging the NLRP3 inflammasome: from signalling mechanisms to therapeutic targets. Nat Rev Drug Discov. 2023 Nov 29. [2]. Klughammer B, et al. A randomized, double-blind phase 1b study evaluating the safety, tolerability, pharmacokinetics and pharmacodynamics of the NLRP3 inhibitor selnoflast in patients with moderate to severe active ulcerative colitis. Clin Transl Med. 2023 Nov;13(11):e1471. |
